Showing 4231-4240 of 7016 results for "".
- Atrasentan Shows Long-Term Kidney Benefit in IgA Nephropathyhttps://reachmd.com/news/atrasentan-shows-long-term-kidney-benefit-in-iga-nephropathy/2487433/Key Takeaways In the main stratum, atrasentan was associated with a smaller eGFR decline over 2.5 years than placebo. An exploratory stratum that included participants receiving an SGLT2 inhibitor also showed a between-group eGFR difference favoring at
- Robot-Assisted Versus Conventional Minimally Invasive Oesophagectomyhttps://reachmd.com/news/robot-assisted-versus-conventional-minimally-invasive-oesophagectomy/2487440/Key Takeaways Five-year overall survival was higher with robot-assisted surgery, and the prespecified non-inferiority criterion was met; an exploratory superiority analysis gave p=0.032. The trial randomly assigned 362 patients in a 1:1 ratio across si
- Small Bites Versus Large Bites in Midline Incision Closurehttps://reachmd.com/news/small-bites-versus-large-bites-in-midline-incision-closure/2487441/Key Takeaways At 13 years, cumulative incisional hernia incidence was 34% with small bites and 49% with large bites. Incisional hernias wider than 20 mm were less frequent after small-bites closure, occurring in 17% versus 34% of patients. Her
- FDA Approves EBGLYSS 8-Week Dosings in Atopic Dermatitishttps://reachmd.com/news/fda-approves-ebglyss-8-week-dosings-in-atopic-dermatitis/2487424/The US Food and Drug Administration (FDA) has approved an every-8-week maintenance dosing regimen for EBGLYSS® (lebrikizumab-lbkz) in adults and adolescents aged 12 years and older weighing at least 40 kg with moderate-to-severe atopic dermatitis, according to an
- Elinzanetant Eases Vasomotor Symptoms In Breast Cancer Trialhttps://reachmd.com/news/elinzanetant-eases-vasomotor-symptoms-in-breast-cancer-trial/2487403/Key Takeaways Larger reductions in symptom frequency than placebo were observed at both prespecified primary time points, weeks 4 and 12. The randomized phase 3 trial enrolled women 18 to 70 years old and used 2:1 assignment to elinzanetant or placebo
- Tumor-Informed ctDNA Stratifies Risk in Anal Squamous Cell Carcinomahttps://reachmd.com/news/tumor-informed-ctdna-stratifies-risk-in-anal-squamous-cell-carcinoma/2487405/Key Takeaways End-of-treatment ctDNA positivity was associated with worse 1-year overall survival, progression-free survival, and locoregional failure, including 96% versus 63% overall survival and 92% versus 44% progression-free survival for ctDNA-negative ver
- Thrive Trial Shows Increase in Home Health Referrals for Medicaid Patientshttps://reachmd.com/news/thrive-home-health-referrals-medicaid/2487391/Key Takeaways Trained discharge planners were more likely to refer eligible patients to home health services than planners who had not yet entered the intervention. Implementation ratings were uniformly high, with acceptability, appropriateness, and fe
- Afrezza ADA 2026 Announcement Highlights Pediatric, Pregnancy, and AID Datahttps://reachmd.com/news/afrezza-ada-2026-announcement-highlights-pediatric-pregnancy-and-aid-data/2487315/Key Takeaways Four Afrezza analyses are slated for ADA 2026 across youth diabetes, gestational diabetes, and automated insulin delivery use. The pediatric work draws from INHALE-1, comparing inhaled insulin with rapid-acting analogs in youth with basel
- Headache on the Hill 2026 Recap: Advocacy, Policy Priorities, And Accesshttps://reachmd.com/news/headache-on-the-hill-2026-recap-advocacy-policy-priorities-and-access/2487314/Key Takeaways The event brought together 282 advocates from 47 states, including patients, caregivers, researchers, clinicians, and about 20 youth advocates. The HEADACHE Act, the Safe Step Act, and the CONNECT for Health Act were the highlighted feder
- PCA SKIN Launches At-Home Triple Exfoliation Peel Padshttps://reachmd.com/news/pca-skin-launches-at-home-triple-exfoliation-peel-pads/2487305/PCA SKIN has launched Triple Exfoliation Peel Pads, an at-home peel treatment designed to support smoother, brighter, healthier-looking skin between professional treatments, according to a company announcement. The Scottsdale, Arizona-based brand said the product builds on more than 35 yea